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Background: Aging is a major non-modifiable risk factor for hypertension. Changes in aging are similar 
to those seen in hypertension in the vasculature. Also, aging increases the vascular dysfunction that occurs 
in hypertension. L-arginase action reduces substrate (L-arginine) availability for the formation of nitric 
oxide (NO). This reduces the level of NO and leads to reduced vasodilation and ultimately, vascular 
dysfunction. This study examines the hypothesis that age-dependent vascular dysfunction in SHRs is 
mediated by arginase. Methods: Young (12-14 weeks) and old (11-12 months) male Wistar and 
spontaneously hypertensive rats (SHR) were used. Mean arterial pressure (MAP) was measured in the rats. 
They were then euthanized and mesenteric resistance arteries (MRAs) and thoracic aortae were excised 
and placed in ice-cold physiological salt solution (PSS). Arterial segments were either snap-frozen in liquid 
nitrogen and stored for immunoblotting studies or cut into 2mm rings for reactivity studies. Cumulative 
concentration-response curves to acetylcholine (Ach; 10-9 – 3x10-5M) and sodium nitroprusside (SNP; 10-
12 – 3x10-5 M) were performed in the absence or presence (30-minute exposure) of L-arginase, 0.05U/ML 
(MRA) or 0.5U/ML (aorta). Vessels were pre-contracted with phenylephrine (PE; 3x10-6M) Results: MAP 
increased during aging in the SHRs p<0.05 but not in the Wistar rats. Arginase impaired the endothelium-
dependent relaxation responses of thoracic aortic and MRA arterial rings to Ach in the old Wistars and 
SHRs (Emax aorta: 29.42±2.19% vs 7.94±1.86%). Arginase also impaired endothelium-independent 
relaxation response to SNP in the old SHRs only (Emax aorta: 88.62±4.10% vs 31.45±10.61%). We also 
observed no differences in the serum arginase activity in the four groups of rats. On the contrary, arginase 
activity in the aortae of young Wistar rats was reduced compared to other groups. Conclusions: Arginase 
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INTRODUCTION   
Hypertension is a major risk factor for cardiovascular 
disease frailty. Hypertension is associated with 
physiological and biochemical changes in the vessel 
wall, characterized by turbulent blood flow, f luid shear 
stress, vascular remodeling, and endothelial dysfunction 
(Mayet and Hughes, 2003). 
Elevated arterial blood pressure in most types of 
hypertension is attributable to increased total peripheral 
resistance,  which results, at least in  part,  from 
alterations in humoral and neurogenic components and 
in vascular endothelial and smooth muscle functions 
(Schiffrin et al.,  2000).  Indeed, altered  vascular  tone, 
 
which is a characteristic feature of human and various 
experimental models of hypertension, has been 
associated not only with impaired endothelium-
dependent vasodilatation and reduced endothelium-
derived relaxing factors, including NO, prostacyclin and 
endothelium-derived hyperpolarizing factor (EDHF) 
signaling, but also with augmented vasoconstrictor 
signaling (Tang and Vanhoutte, 2010). 
Numerous studies have demonstrated the link 
between the aging process and cardiovascular 
dysfunction. Aging is a major non-modifiable risk factor 
for hypertension. The prevalence of hypertension is 
more than doubled in the elderly than in the young 
population (Ong et al., 2007). Structural, functional and 
mechanical changes occur with aging. These changes are 
similar to those seen in the vasculature in hypertension. 
Also, aging increases the vascular dysfunction that 
occurs in hypertension. The characteristic features of 
vascular dysfunction in hypertension are also present in 
aging and these include: 
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Inflammation, turbulent blood flow, oxidative stress, 
fluid shear stress, endothelial dysfunction and vascular 
remodeling (Goeres et al., 2014). Despite the fact that 
aging is a major risk factor for hypertension, there are 
relatively less number of research, clinical trials on the 
treatment of hypertension in older adults; this could be 
as a result of:
 Drug metabolism in the older adults (Sera and 
McPherson, 2012), Medications and co-morbidities 
(Benetos et al., 2015) and orthostatic hypotension 
(Belmin et al., 2000). 
Dysfunctional vascular endothelium has been reported 
to be associated with various forms of human and 
experimental hypertension (Luscher et al, 1987).  
 
 
Fig. 1. The role of the endothelium-derived vasoactive substances in the development of hypertension. NO: nitric oxide; EDHF: 
endothelium derived hyperpolarizing factor.  
 
 
The endothelial cells release vasoactive factors that 
modulate vascular tone. NO and endothelium derived 
hyperpolarizing factors are vasorelaxants released by the 
endothelium. The endothelium also secretes vaso-
constrictive factors including: endothelin1, angiotensin 
II, and superoxide ions.  Thromboxane (Vanhoutte 1989; 
Sandoo et al., 2010). Under physiological conditions, 
there is a balance between vasoconstrictive and 
vasorelaxants factors released by the endothelial cells. 
This balance is altered in hypertension and this leads to 
endothelial dysfunction, decrease in NO production and 
vasodilation (Versari et al., 2009). Different 
mechanisms have been proposed for the decreased NO 
seen in hypertension. As shown in figure 1, in normal 
physiological conditions, the endothelium secretes 
vasoconstrictive and vasodilatory substances, but during 
hypertension, this balance is tilted therefore, the 
endothelium secretes more of vasoconstrictive 
substances, which leads to increased vasoconstriction 
and reduced vasorelaxation. 
Arginase is a ureohydrolase enzyme that converts L-
arginine into L-ornithine and urea. Two isoforms of 
arginase have been cloned (Haraguchi et al., 1987). Its 
presence in the liver was first described by Krebs and 
Henseleit in 1929 (Jenkinson et al., 1976) and crude 
preparation were reported as far back as 1931 (Salaskin 
and Solowjew 1931, and Waldschmidt-Leitz et 
al., 1931). In 1956, the “partial” purification was further 
improved by Robbins and Shields. (Robbins and Shields 
1956). A study by Buga et al., (1996) reveals for the first 
time that substantial arginase activity is present 
constitutively in rat aortic endothelial cells. The 
presence of arginase I and II as well as their activity and 
expression in cultured vascular smooth muscle and 
endothelial cells have been reported (Zhang et al., 2001; 
Johnson et al., 2005). Upregulation of arginase has been 
reported to be associated with aging and cardiovascular 
diseases (Toque et al., 2013). Studies by Johnson et al, 
2005, showed that enhanced vascular arginase activity 
contributes to endothelial dysfunction in Dahl-S rats 
with salt-induced hypertension. 
The roles of arginases in vascular disease, pulmonary 
disease, infectious disease, and cancer have been studied 
(Morris 2002, Santhanam et al. 2008,). 
Radiometric assays showed that in pathological 
conditions, arginase, compared to eNOS, is, at baseline, 
the major metabolic pathway for l-arginine utilization in 
cell extracts (Bachetti et al., 2004). 
Arginase inhibitors have been used to probe the role of 
arginase in the regulation of NO-mediated smooth 
muscle relaxation in the gastrointestinal tract as well as 
in penile and clitoral corpus cavernosum tissues (Kim et 
al., 2001). Furthermore, the endothelial dysfunction 
observed with various forms of hypertension can be 
reversed by the administration of L-arginine (Chen and 
Sanders 1991; 1993; Hu and Manning, 1995). Increased 
arginase expression has been reported in hypertensive 
disorders and is associated with decreased NO 
bioavailability and enhanced vascular reactivity 
(Johnson et al, 2005; Demougeot et al, 2005). 
Arginase action reduces substrate (L-arginine) 
availability for the formation of nitric oxide (NO). This 
reduces the level of NO and leads to reduced 
vasodilation and ultimately, vascular dysfunction. This 
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study tests the hypothesis that the age dependent 
vascular dysfunction in spontaneously hypertensive rats 




Young (12-14 weeks) and old (11-12 months) male 
Wistar and spontaneously hypertensive rats were used in 
this study. They were purchased from Envigo RMS, Inc. 
and all rats were maintained in GM500 individually 
ventilated cages (Animal Care Systems), at 21°C, 50–
70% humidity, on a 12-hour light/dark cycle, chow and 
water were made available ad libitum. All animal 
handling procedures were performed in accordance with 
the Guide for the Care and use of Laboratory Animals of 
the National Institutes of Health (NIH) and were 
reviewed and approved by the Institutional Animal Care 
and Use Committee of Augusta University.  
 
Blood pressure measurements: 
Mean arterial pressure (MAP) was measured in the rats 
under anaesthesia (isoflurane 1.5%, via inhalation). The 
animal was carefully dissected to expose the femoral 
artery; the catheter was inserted into the femoral artery 
while the other end was connected to the pressure 
transducer coupled to a Powerlab system (Powerlab 
4SP/ML750). They were then euthanized and 5ml of 
blood was drawn from the heart to obtain serum for the 
assay of arginase activity. 
 
Vascular function 
Mesenteric resistance arteries (MRAs) and thoracic 
aortae from young and old wistar and Spontaneously 
hypertensive rats (SHRs) were excised and placed in 4˚C 
Physiological salt solution (PSS) containing (mmol/L): 
NaCl (130), NaHCO3 (14.9), KCl (4.7), KH2PO4 (1.18), 
MgSO4·7H2O (1.18), CaCl2·2H2O (1.56), EDTA 
(0.026), and glucose (5.5) (all Sigma-Aldrich). Thoracic 
aortae and second order MRAs were carefully cleaned 
of adhering perivascular adipose tissues under light 
microscopy in ice-cold PSS and cut into 2mm segments, 
divided into two groups; one group of arterial segments 
was denuded of their endothelium. The MRA 
endothelium was denuded by rubbing the lumen with a 
hair shaft (McCarthy et al., 2018) while the aorta was 
denuded by gently rubbing the lumen with tweezers. The 
MRA rings were mounted on DMT wire myographs 
(Danish Myo Tech, Aarhus, Denmark) and were 
normalized to their optimal lumen diameter for active 
tension development which was determined based on the 
internal circumference (L0) t0 90% of what the vessels 
would have if they were exposed to a passive tension 
equivalent of 100mmHg (L100) transmural pressure 
(Mulvany and Halpern, 1976). The diameter (I1) was 
then determined according to the equation I1 = L1/π, 
using the software specific for normalization of 
resistance arteries (DMT Normalization Module; 
LabChart v.5.5.6, AD Instruments). The aortic rings 
were mounted on DMT pin myograph (Danish Myo 
Tech, Aarhus, Denmark) and tension was set to a basal 
force of 30mN. Arteries were then bathed in PSS 
maintained at 37˚C, bubbled continuously with 5% 
CO2and 95% O2for 30 minutes and rinsed three times at 
10-minute intervals. Thereafter, the vessels were 
initially contracted with 120mM KCL PSS (the vessels 
were considered viable only if they contracted to a force 
greater than 10mN in response to 120mM KCL). 
Endothelium integrity was then tested by contracting the 
MRA rings with 3x10-6M Phenylephrine (PE) followed 
by relaxation with 3x10-6 M Acetylcholine (ACH) and 
the aortic ring endothelium denudation was considered 
successful if arterial rings relaxed less than 25% to Ach 
(Ebeigbe and Aloamaka, 1985). Arterial rings were 
washed with fresh PSS three times and rested for 10 




Evaluation of endothelium-dependent relaxation 
responses 
MRAs and aortae with confirmed intact endothelium 
were initially contracted with PE (3x10-6M); when the 
contraction attained a plateau, cumulative concentration-
response tests to ACH (10-9-10-5M) were performed. 
Thereafter, the rings were washed thrice with fresh PSS 
and allowed to rest for 20 minutes. Subsequently, the 
above relaxation-response protocol was repeated 
following incubation of the rings for 30 minutes with 
either 0.05U/ML (MRA) or 0.5U/ML (aorta) L-arginase. 
 
Evaluation of endothelium-independent relaxation 
responses 
MRAs and aortae with confirmed denuded endothelium 
were initially contracted with PE (10-6M); when the 
contraction attained a plateau, cumulative concentration-
response tests to SNP (10-12-10-5M) were performed. 
Thereafter, the rings were washed thrice with fresh PSS 
and allowed to rest for 20 minutes. This was followed by 
a repeat of the above relaxation-response tests in rings 
incubated for 30 minutes, with either 0.05U/ML (MRA) 
or 0.5U/ML (aorta) L-arginase. 
 
Arginase activity Assay 
Arginase activity was measured using the arginase 
activity assay kit (catalog number: MAK112) purchased 
from Sigma-Aldrich (St. Louis, MO, USA). It provided 
a simple and direct protocol for measuring arginase 
activity in the serum and tissues. 
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Thoracic aortae and MRAs were cleaned of perivascular 
adipose tissue and snap-frozen in liquid Nitrogen. 
Expression of arginase, and eNOS (endothelial nitric 
oxide synthase), were measured. Arterial segments were 
homogenized in a cold protein extraction buffer.  Equal 
amounts of protein were separated using 6, 10 or 15% 
SDS-PAGE.  Gels were transferred to nitrocellulose 
membranes and standard immunoblotting procedures 
were done using primary antibodies indicated above. 
Immunoreactive bands were visualized with the 
enhanced chemiluminescence detection system and 
quantified using Alpha Imager software. β-actin was 
used to normalize expression. 
 
 
Fig. 2: Mean arterial blood pressure (mmHg) of young and 
old SHR and Wistar rats. Values presented as mean ±SEM of 
6 rats in each group.* p<0.05 compared to young SHR; # 
p<0.05 compared to age-matched Wistars 
 
Statistical Analysis 
Data are expressed as means ± S.E.M. of 6 rats per 
group; statistical differences were calculated using 
Student’s t-test, one-way and two-way ANOVA with 
repeated measures followed by Bonferroni post hoc test. 
Significance was set at p<0.05. All statistical tests were 




Blood Pressure of Rats 
We observed a significant difference in the MAP 
(mmHg) of the young SHRs compared to the young 
wistar rats (132 ± 10.25 vs 104.4 ± 3.012 p<0.05); the 
old SHRs compared to the old wistar rats (166.2 ± 1.9 vs 
92.08 ± 1.545 p<0.05) and between the old and young 
SHRs (166.2 ± 1.9 vs 132.3 ± 10.25 p<0.05), but no 
difference was observed between the young and old 




Fig. 3: Evaluation of arginase activity in serum (A) and 
thoracic aortae (B) of young and old wistar rats and 
SHR. Mean ± S.E.M. of 6 rats. * p<0.05 compared to 
respective controls using one-way ANOVA with 




Serum Arginase Activity 
Serum arginase activity was not significantly different in 
the four groups of rats; however, aortic arginase activity 
was increased in the old Wistars and SHRs.  
 
Western Blot Studies  
The expression of arginase 1 and eNOS was examined 
in the thoracic aortae of the groups of rats, to determine 
if it there will be differences between the groups of the 
rats. Arginase expression was lower in the young wistar 
aortae compared to other groups. There were no 
differences in the eNOS expression in these groups of 
rats. 
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Fig. 4: Assessment of arginase 1(A) and eNOS (B) 
expression in the thoracic aortae of the groups of rats. 
Arginase expression was lower in the young wistar aortae 
compared to other groups. There were no significant 
differences in the eNOS expression in these groups of rats. 
Mean ± S.E.M. of 4 rats. * p<0.05 compared to control using 
one-way ANOVA with Bonferroni post hoc test. 
 
Concentration Dependent Responses to Acetylcholine in 
Arterial Ring Segments of Young and old SHR and 
Wistar Rats 
To test our hypothesis that age dependent vascular 
endothelial dysfunction is mediated by arginase, 
concentration dependent relaxation responses of young 
and old SHR and wistar thoracic aortic rings and MRA 
segments to ACH [10-9 – 3x10-5 M] before and after 
incubation with L-Arginase [0.5U/ML] for 30 minutes 
were evaluated. We observed a significant decrease in 
concentration dependent relaxation response to ACH 
[10-9 – 3x10-5 M] in the old SHR rings incubated with 
L-arginase compared with the rings without incubation 
(p<0.05); but no significant difference was observed in 
the young. 
 
Fig. 5: Evaluation of concentration dependent relaxation 
responses of thoracic aortic ring segments from young and old 
rats to ACH [10-9 – 3x10-5 M] before and after incubation with 
L-Arginase [0.5U/ML] for 30 minutes. A: SHR, B: Wistar 
rats. Vessels were pre-contracted with 3µM phenylephrine. 
Mean ± S.E.M. of 6 rats * p<0.05 compared to controls. 
 
 
Concentration Dependent Responses to Sodium 
Nitroprusside in Arterial Ring Segments of young and 
old SHR and Wistar Rats 
In order to test if the vascular dysfunction mediated by 
Arginase is only in the endothelium, the endothelium 
was denuded and the concentration dependent relaxation 
responses of thoracic aortic and mesenteric resistance 
arterial ring segments to SNP [3x10-12 – 3x10-5 M] 
before and after incubation with L-Arginase [0.5U/ML] 
for 30 minutes were evaluated. Vessels were pre-
constricted with 3µM phenylephrine. Mean ± S.E.M. of 
6 rats * p<0.05 compared to old SHR. We observed a 
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Fig 6: Evaluation of concentration dependent relaxation 
responses of mesenteric resistance arterial ring segments from 
young and old rats to ACH [10-9 – 3x10-5 M] before and after 
incubation with L-Arginase [0.5U/ML] for 30 minutes. A: 
SHR, B: Wistar rats. Vessels were pre-contracted with 3µM 
phenylephrine. Mean ± S.E.M. of 6 rats * p<0.05 compared to 
controls. 
 
significant decrease in concentration dependent 
relaxation response to SNP [3x10-12 – 3x10-5 M] in the 
old SHR rings incubated with L-arginase compared with 
the rings without incubation (p<0.05). No difference was 
observed in all other groups. 
 
DISCUSSION  
Studies have reported that the serum level of arginase is 
increased in some disease conditions and this could be a 
diagnostic tool in the prognosis of such diseases (Pernow 
and Jung, 2013). Studies, using animal models of 
hypertension have reported increases in arginase activity 
( Gudi et al., 1996; Rodriguez et al., 2000; Zhang et al., 
2004; Johnson et al., 2005; Demougeot et al., 2007;) in 
the arteries of these animals. 
There were no significant differences in the serum 
arginase activity in the four groups of rats, but arginase 
activity in the thoracic aorta of young wistar was reduced 




Fig. 7: Evaluation of concentration dependent relaxation 
responses of thoracic aortic arterial ring segments from young 
and old rats to SNP [3x10-12 – 3x10-5 M] before and after 
incubation with L-Arginase [0.5U/ML] for 30 minutes. A: 
SHR, B: Wistar rats. Vessels were pre-contracted with 3µM 
phenylephrine. Mean ± S.E.M. of 6 rats. *p< 0.05 compared 
to the other groups. 
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Fig. 8: Evaluation of concentration dependent relaxation 
responses of mesenteric resistance arterial ring segments from 
young and old rats to SNP [3x10-12 – 3x10-5 M] before and 
after incubation with L-Arginase [0.5U/ML] for 30 minutes. 
A: SHR, B: Wistar rats. Vessels were pre-contracted with 
3µM phenylephrine. Mean ± S.E.M. of 6 rats. *p< 0.05 
compared to the other groups. 
 
There were no significant differences in the serum 
arginase activity in the four groups of rats, but arginase 
activity in the thoracic aorta of young wistar was reduced 
compared to the other groups. Increased arginase 
activity has been reported in arteries of animal models of 
hypertension ( Rodriguez et al., 2000; Johnson et al., 
2005; Demougeot et al., 2007; Bagnost et al., 2009). Our 
results showed that arginase expression was less in the 
young wistar compared to other groups. This is 
consistent with literature that arginase is expressed more 
in aging and hypertension. 
ACh acts on the muscarinic receptors of the endothelial 
cells and causes a release of nitric oxide that results in 
relaxation of the vascular smooth muscles. This 
relaxation of arterial smooth muscle by ACh is 
dependent on the presence of the endothelium (Furchgott 
and Zawadzki, 1980). They observed that removal of the 
endothelium by rubbing the internal surface of the blood 
vessels led to impaired Ach induced 
relaxation.(Furchgott and Zawadzki, 1980). 
We examined the effect of arginase on the Ach induced 
endothelium dependent relaxation in young and old 
normotensive and hypertensive rats pre-contracted with 
3µM phenylephrine. Arginase competes with eNOS for 
L-arginine, the substrate for nitric oxide production and 
reduces the availability of nitric oxide, thereby reducing 
the relaxation of the vascular smooth muscle (Durante et 
al.,  2007). This attenuation in vascular relaxation to Ach 
was observed in the thoracic aortic and mesenteric 
resistance arterial ring segments of old wistar and 
spontaneously hypertensive rats. This indicates that 
arginase inhibited the production of NO by eNOS in the 
endothelium of the old rats by using up all the L-
arginine. Arginase is broken down to release urea and L-
ornithine (Ash, 2004). Urea is readily excreted by the 
kidney, but L-ornithine is broken down by Ornithine 
decarboxylase to polyamines and Ornithine amino 
transferase to L-proline.  Polyamines have been shown 
to impair endothelium dependent vasoconstriction 
(Tabor and Tabor, 1984). On the other hand, arginase 
had no effect on the endothelium dependent relaxation 
responses to ach in the thoracic aortic and mesenteric 
resistance arterial ring segments of young wistar and 
spontaneously hypertensive rats. This may be as a result 
of the abundance of L-arginine in the endothelium of the 
arterial rings of these young animals, so even in the 
presence of arginase, there was enough substrate for 
eNOS to convert to NO. 
To test if the vascular dysfunction mediated by Arginase 
is endothelium-dependent, we denuded the endothelium 
and evaluated the concentration dependent relaxation 
responses of thoracic aortic arterial ring segments to 
sodium nitroprusside (SNP). SNP releases NO in the 
circulation by binding to oxyhaemoglobin to release NO. 
It therefore supplies NO for the relaxation of the vascular 
smooth muscle (Friederich et al., 1995). The NO 
supplied by SNP diffuses into the vascular smooth 
muscle cells to cause vasorelaxation; therefore, the 
relaxation responses to SNP are not endothelium 
dependent. We observed that arginase attenuated 
vascular relaxation to SNP in the thoracic aortic and 
mesenteric resistance arterial ring segments of old 
spontaneously hypertensive rats. On the other hand, 
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arginase had no effect on the endothelium independent 
relaxation responses to SNP in the thoracic aortic and 
mesenteric resistance arterial ring segments of young 
and old Wistar and young spontaneously hypertensive 
rats. These observations suggest that arginase in addition 
to inducing endothelial dysfunction also induces 
vascular smooth muscle dysfunction the old 
hypertensive rats. The impaired relaxation to SNP in the 
old SHRs is indicative of possible arginase induced 
impairment of the downstream signaling pathway of 
NO-mediated relaxation.  
 
CONCLUSION 
The results of this study suggest that arginase impairs 
both endothelium-dependent and –independent 
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